Fig. 3.

TP53^R248L mutation promotes the progression of GBM and enriches inflammation-related signatures. a Tumor grade-dependent enrichment of the TP53^R248L signature in patients with low-grade glioma or GBM (***P < 0.001; one-way ANOVA). b–d Kaplan–Meier survival plots showing the overall survival of patients with respect to the TP53^R248L signature enrichment. e GSEA demonstrating the enrichment of inflammation-related signatures in TP53^R248L-overexpressing 19NS GBM cell line. f GSEA showing the enrichment of chemotaxis-associated signatures in TP53^R248L-overexpressing 19NS GBM cell line. g Correlations between TP53^R248L signature and inflammation/chemotaxis-related signatures in the TCGA GBM patient expression dataset. h GSEA showing the enrichment of inflammation/chemotaxis-related signatures in various types of cancer with TP53 DNA binding domain (DBD)-mutated (MUT) or non-mutated (non-MUT)